CHILDHOOD-ONSET GRAVES’ DISEASE
Corresponding author:
[email protected]
Received
15 September 2020
Revised
27 September 2020
Accepted
03 October 2020
Available Online
15 November 2020
Abstract
HYPERTHYROIDISM IS CAUSED BY A THYROID -STIMULATING HORMONE (TSH) RECEPTOR THAT STIMULATES AUTOANT IBODIES THAT CAUSE EXC ESS PRODUCT ION A ND GROWTH OF THYROID HORMONES. HYPERTHYROIDISM IN CHILDHOOD IS OFTEN CAUSED BY GRAVES -BASEDOW DISEASE. APART FROM CASES OF TRANSIENT NEONATAL HYPERTHYROIDISM THAT DEVELOP FROM MOTHERS WITH ACTIVE GRAVE S-BASEDOW DISEASE , HYPERTHYROIDISM OCCU RS LESS IN PRESCHOOL CHILDREN AND RARELY IN CHILDHOOD. SYMPTOMS OF HYPERTHYR OIDISM INCLUDE EXCESS PHYSICAL ACTIVITY, TREMOR, TACHYCARDIA, FLUSHING, PALPITATIONS, WEIGHT LOSS, ACCELERATED LINEAR GROWTH, REDUCED BONE MI NERALIZATION, AND POOR SCHOOL PERFORMAN CE. IN CHIL DHOOD GRAVES’ DISEASE, OPHTALMOPATHY OCCURS IN LESS THAN 50 PERCE NT OF PATIENTS AND IS USUALLY MILD WHEN PRESENT. WE'RE PRESENTING THE CASE OF A 2,8 YEARS OLD GIRL WITH BASEOW -GRAVES DISEASE HOSPITALIZED FO R BILATERAL EXOPHTHALMIA. SHORTLY AFTER THE FIRST YEAR, THE BABY GIRL DEVELOPED SIGNS OF HYPERTHYROIDISM, BUT THE M OTHER NEGLECTED THE PRESENTATION TO THE DOCTOR. THE MOST PROMINENT FEATURES WERE THE ACCELERATION OF SKELETAL MATURATION, LINEAR GROWTH AND C HARACTERISTIC APP EARANCE OF THE FACE. L ATE MANIFES TATIONS WERE REVERSIBLE FOLLOWING TREATMENT WITH ANTITHYROID SYNTHESIS.
Keywords
GRAVES- BASEDOW DISEASE
BILATERAL EXOPHTHALMIA
HYPERTHYROIDISM
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Brix TH, Kyvik KO, Hegedus L : What is theevidence of genetic factors in the etiology of Graves’ disease? A brief review. Thyroid1998; 8: 727–734.
[2]
Brix TH, Kyvik KO, Christensen K, HegedusL : Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts . J Clin EndocrinolMetab 2001; 86: 930 – 934.
[3]
Saitoh O , Nag ayama Y : Regulation of Graves’ hy perthyroidism with naturally occurring CD4+CD25+ regulatory T cells in a mouse model. Endocrinology 2006; 147: 2417–2422.
[4]
A. P. Weetman © Humana Press, Totowa, NJ: Contemporary Endocrinology: Autoimmune Diseases in Endocrinology 2008; eISBN: 978-1-59745-517-6.
[5]
Delange F, Fisher DA . The thyroid. In: Brook CGD, ed. Clinical paediatric endocrinology. 3rd Ed. Oxford: Blackwell Science, 1995:397-433.
[6]
Shenker A . G protein -coupled receptor structure and functions; the imp act of disease -causing mutations, Baillieres Clin Endocrinol Metab 1995; 9:427-51
[7]
Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effects of treatment J Clin Endocrinol Metab 1994; 78:955-9.
[8]
Menkes JH,Hu rvitz C GH, M cdiarmid SV , Williams RG. Neurologic manifestations of systemic disease . In : Pine JW, ed. Textbook of child neurology (Menkes). 5th Ed. Baltimore: Williams and Wilkins, 1995:873-923.
[9]
W. Chan, GWK Wong -Ophthalmopathy in childh ood Graves’ disease-Br. J Ophthalmo 2002:86:740- 742.
[10]
Rivkees/SA, Aklarck, Freemark M .-clinical review 99. The management of Graves’ disease in children with special emphasis on radioiodine treatment J. Clin. Endocrinol Metab. 1998;83;3767-76.
[11]
Solomon DH, Beck JC, Vanderlaan WP. Prognosis of hyperthyroidism treated by antithyroid drugs.J Am Med Assoc 1953; 152: 201–205.
[12]
Reinwein D, Benker G, Lazarus JH, Alexander WD . A prospective randomised trial of antithyroid drug dose in Graves’ disease therapy. J Clin Endocrinol Metab 1993; 76: 1516–1521.
[13]
Engler H, Taurog A, Luthy C, Dorris ML . Reversible and irreversible inhibition of thyroid peroxidase catalysed iodination by thioureylene antithyroid drugs. Endocrinology 1983; 112: 86–95.
[14]
Marchant B, Lees JF, Alexander WD. Antithyroid drugs. Pharmacol Ther B 1978; 3: 305–348.
[15]
Okamura K, Ikenoue H, Shiroozu A, Sato K, Yoshinari M, Fujishima M. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves’ hyper thyroidism. J Clin Endocrinol Metab 1987; 65: 719–723.
[16]
Lavard L, Ranlov I, Perrild H, Andersen O, Jacobsen BB. Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study. Eur J Endocrinol 1994; 130:565-568.
[17]
Juliane Léger, Jean Claude Carel. Hyperthyroidism in Childhood: Causes, When and How to Treat. J Clin Res Pediatr Endocrinol. 2013 Mar; 5(Suppl 1): 50–56.
[18]
Torring O, Tallstedt L, Wallin G, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodi ne-a prospective, randomized stud y. J Clin Endocr inol Metab 1996; 8 1:2986– 2993.
[19]
Okamura K, Ikenoue H, Shiroozu A, Sato K, Yoshinari M, Fujishima M . Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves’ hyp erthyroidism. J Clin Endocrinol Metab 1987; 65: 719–723.
[20]
Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352: 905–917.
[21]
Smith BR, Bolton J, Young S, et al. A new assay for thyrotropin receptor autoantibodies. Thyroid 2004; 14: 830–835.
[22]
Gary Butl er, Jeremy Kirk -Paediatric Endocr inology and Diabete s,Oxford Spe cialist Handbook 2011-ISBN 978-0-19-923222-2.
[23]
Alenazi B, Alenazi A, Alshaya A et al. Pediatric graves’ disease: a case re port. Int J Health Sci Res. 2017; 7(12):330-333.